SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing strong bullish momentum as investors anticipate a major buyout, fueled by robust Briumvi revenue growth and highly anticipated subcutaneous clinical data. The community is actively discussing the potential for a massive short squeeze, with many long-term shareholders holding firm in expectation of a significant valuation premium.

Sony Group Corp. engages in the development, design, manufacture, and sale of electronic equipment, instruments, devices, game consoles, and software for consumers, professionals and industrial markets. It operates through the following segments: Game and Network Services, Music, Pictures, Entertainment Technology & Services, Imaging and Sensing Solutions, Financial Services, and Others. The Game and Network Services segment deals with gaming machines, software and network services. The Music segment produces and publishes music and provides image media platforms. The Pictures segment handles film production, television program creation, and media networks. The Home Entertainment and Sound segment offers LCD televisions, home audio, Blu-ray Disc players and recorders, and memory-based portable audio devices. The Imaging and Sensing Solutions segment includes the image sensors business. The Financial Services segment manages the life insurance and non-life insurance operations and banking business. The Others segment consists of various operating activities, including the disc manufacturing and recording media businesses. The company was founded by Akio Morita and Masaru Ibuka on May 7, 1946 and is headquartered in Tokyo, Japan.

Sony Group Corporation - ADR

Sony Group Corporation

Sony is trending as investors weigh the company's aggressive shift toward a high-margin, all-digital gaming model against community backlash regarding the potential phasing out of physical discs. Traders are also closely watching the firm's strategic pivot into 'physical AI' and robotics, viewing these as long-term growth catalysts alongside its core entertainment and image sensor divisions.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as the community debates its long-term potential following recent integrations with Google Cloud and the launch of the ASI:Chain DevNet. Investors are actively discussing whether to accumulate at current price levels or wait for deeper support, while sentiment remains divided between those betting on the long-term utility of autonomous AI agents and skeptics concerned about token supply and recent market volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending as the community debates intense allegations of administration corruption, financial self-enrichment, and the political hijacking of national anniversary celebrations. Investors and critics alike are fixated on the company's volatile market performance and the broader implications of these ongoing legal and ethical controversies.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is seeing significant trading activity as investors react to extreme volatility and leveraged plays tied to MicroStrategy's Bitcoin treasury strategy. The community is heavily divided, with some traders actively scalp-trading intraday price swings for rapid gains, while others express intense frustration over long-term value erosion and the ongoing risks of reverse stock splits in leveraged ETFs.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is gaining significant traction due to institutional buying momentum and growing anticipation around potential legislative catalysts like the Clarity Act. Community sentiment remains split, with bulls pointing to the token's role in stablecoin infrastructure and institutional adoption, while skeptics continue to debate its long-term utility against alternative blockchain technologies.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending as investors digest a strong earnings report and raised guidance against a backdrop of extreme short-term stock appreciation. The community is actively debating the company's valuation, the impact of recent acquisitions, and whether cybersecurity will sustain its AI-driven momentum or face a correction after a parabolic run.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as the community actively debates whether the recent price action signals a lasting bottom or a continued downtrend, often polarizing between long-term supporters and vocal bears. Traders are fixated on key resistance levels and broader market macro-indicators, frequently engaging in heated discussions about the coin's future utility and speculative nature.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd is seeing significant market turbulence following its latest quarterly results, with shares facing sharp volatility as investors weigh robust revenue growth against concerns over rising operational expenses and intensifying regional competition. The community is deeply divided between those viewing the steep sell-off as a prime long-term accumulation opportunity for a dominant e-commerce and fintech player, and those wary of the stock's persistent downtrend and ongoing insider selling activity.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is surging on strong investor optimism following reports of a potential FDA fast-track for psychedelic treatments and institutional accumulation ahead of key upcoming clinical data. The community is actively discussing the stock's role as a first-mover in treatment-resistant depression and closely tracking institutional activity and legislative shifts that could accelerate the commercialization of its COMP360 program.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to...

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting...

Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II

RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.

RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome Therapy

Equity

The U.S. Food and Drug Administration has agreed to reconsider Regenxbio’s application for its experimental gene therapy Navsunli.

Stocks Drift As Chips Extend Gains, Oil Slides On Positive US-Iran Talks

Stocks Drift As Chips Extend Gains, Oil Slides On Positive US-Iran Talks

 Futures are modestly lower coming off the US holiday weekend, after equities finished higher last week with both Dow and Russell clocking new ATHs and SPX finishing in the green for the 11th time in the last 12...

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS...

Are Options Traders Betting on a Big Move in REGENXBIO Stock?

Investors need to pay close attention to RGNX stock based on the movements in the options market lately.

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.

OCGN's Catalyst Calendar for Trial Data and Filings Through 2028

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway...

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.25	--	--	N/A
Q1 '26	-$1.34	-$1.72	-28.65%	MISSED
Q4 '25	-$0.88	-$1.30	-48.52%	MISSED
Q3 '25	-$1.30	-$1.20	7.81%	BEAT
Q2 '25	-$0.94	-$1.38	-47.14%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

RGNXRegenxbio Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest RGNX News